Errant Gene Therapeutics becomes San Rocco Therapeutics

Errant Gene Therapeutics Becomes San Rocco Therapeutics twenty-eight years after its establishment.

Errant Gene Therapeutics was founded in 1993, after founder Pat Girondi’s son was diagnosed with Thalassemia, a cousin disease to Sickle Cell Anemia.

In 2007, with the help of researchers from Memorial Sloan Kettering, Cornell and National Institute of Health, EGT became the first entity to pass the FDA Recombinant DNA Committee for gene therapy in Sickle Cell Disease and Beta Thalassemia. EGT was the first company to get Orphan Drug Designation for Thalassemia in the US and Europe and first to produce a commercial batch (8-10 patients) of gene therapy for Sickle Cell Disease and Thalassemia. EGT is the company with the longest track record of treating US patients and the only company with experience in both harsh and soft chemotherapeutic prep-regimens.

Errant Gene will become San Rocco Therapeutics (SRT). San Rocco is the patron saint of hopeless disease. EGT opened Centro Medico San Rocco in Altamura, Italy, in 1995 and was free of charge for dozens of patients suffering hemoglobinopathies.

The SRT vector uses the natural wild type beta globin gene. Other companies, such as Bluebird Bio, used a mutant gene. To date, four patients have been treated with the EGT vector with no incidence of Clonal Dominance and no incidence of AML leukemia.

Dr. Lucio Luzzatto, former Chair of the ASGCT’s Ethics Committee recently commented on the barrier to access for most patients and was quoted in Lancet (Vol 8, April 2021), “Nearly all recently introduced targeted drugs are unavailable or unaffordable.” Girondi adds, “Most Orphan Disease research is paid for by the taxpayer through public grants and not for profits. It’s time to ‘weed the greed.’ We cannot have taxpayer-sponsored therapies turn into products which patients cannot afford because of gross executive compensation.”

San Rocco aims for a one-time price of $700,000. The price will be lowered as more patients are treated. This is more than $1,000,000 less than Bluebird’s price of $1,800,000 and in line with EMEA and FDA wishes of Orphan Disease products which are affordable to patients.

EGT CEO, Pat Girondi says, “Born and raised a true US capitalist, the first thing I do as a leader is to sacrifice myself. A dollar I use is a dollar less for research. I have an allergic reaction to the sheets if my hotel room costs more than $100. I’m not paying for that room. The patients are.”

View the rest of the article here

View the PDF